Applied Poleramic (United States)

Abstract The La Plata basin is the second largest basin of South America and has supported important river fisheries for more than a century. In this paper, we evaluate for the first time the historical trends of landings of 21 fish taxa and the recent population trends of 27 species of commercial fishes in the lower La Plata basin (Argentina). We compiled three kinds of data sets: Total fishery landings (between 1934 and 1986) and exports (1994‒2019), fisheries monitoring programs of Chaco and Santa Fe provinces in the Paraná River (2009‒2019), and surveys of fish populations in the Upper (Corrientes, 1993‒2020) and Middle (EBIPES, 2005‒2020) Paraná River. The analysis of the historical landings showed more species declining in the lower portion of the basin than in the upper basin. Regarding recent population trends, Pimelodus spp., Hoplias spp., Salminus brasiliensis, Luciopimelodus pati, and Ageneiosus spp. declined in more than one region, while Megaleporinus spp., Pterodoras granulosus, and Oxydoras kneri showed stable to positive trends, with the other species varying in their trends between regions. These tendencies could be associated to a combination of factors such as overfishing and environmental changes that would require an ecosystem approach for their adequate management.

This research aimed at analyzing the reception of literary works in the school's context, considering social and theoretical problems that concern the teaching of literature and the teacher's role.

This department column highlights translation of research into healthcare quality practice. Achieving the highest quality in healthcare requires organizations to understand care delivery and to develop and design process efficiencies. The improvement process may be enhanced through a partnership between the healthcare facility and an affiliated school of nursing. The purpose of this article was to describe the process for developing a large-scale improvement project focused on enhancing care transitions within an academic medical center using an academic-practice partnership model.

This department column highlights translation of research into healthcare quality practice. Achieving the highest quality in healthcare requires organizations to understand care delivery and to proactively mitigate risks in care delivery processes. The purpose of this article was to describe the process for using the failure modes and effects analysis process to provide evidentiary support and proactive risk mitigation for the establishment of a comprehensive vascular access team within an academic medical center.

Electrical reliability can be measured by taking a systematic approach to documenting PM (preventive maintenance) records with a metric derived from its discovery finds. These finds, however minor, are leading indicators to equipment failures. Documenting and reviewing them justifies electrical PM programs, measures PM effectiveness, and optimizes PM intervals.

We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-104A and further reduced to the amine and hydroxyl-amine nitrogen mustards that induce DNA cross-linking in hypoxic cells under low oxygen concentrations. In this phase I/II study, patients with relapsed/refractory acute myeloid leukemia (n=40) after 1 or 2 prior treatments or acute lymphoblastic leukemia (n=10) after any number of prior treatments received PR104; dose ranged from 1.1 to 4 g/m(2). The most common treatment-related grade 3/4 adverse events were myelosuppression (anemia 62%, neutropenia 50%, thrombocytopenia 46%), febrile neutropenia (40%), infection (24%), and enterocolitis (14%). Ten of 31 patients with acute myeloid leukemia (32%) and 2 of 10 patients with acute lymphoblastic leukemia (20%) who received 3 g/m(2) or 4 g/m(2) had a response (complete response, n=1; complete response without platelet recovery, n=5; morphological leukemia-free state, n=6). The extent of hypoxia was evaluated by the hypoxia tracer pimonidazole administered prior to a bone marrow biopsy and by immunohistochemical assessments of hypoxia-inducible factor alpha and carbonic anhydrase IX. A high fraction of leukemic cells expressed these markers, and PR104 administration resulted in measurable decrease of the proportions of hypoxic cells. These findings indicate that hypoxia is a prevalent feature of the leukemic microenvironment and that targeting hypoxia with hypoxia-activated prodrugs warrants further evaluation in acute leukemia. The trial is registered at clinicaltrials.gov identifier: 01037556.

PR-104 is a phosphate ester that is systemically converted to the corresponding alcohol PR-104A. The latter is activated by nitroreduction in tumours to cytotoxic DNA cross-linking metabolites. Here, we report a population pharmacokinetic (PK) model for PR-104 and PR-104A in non-human species and in humans. A compartmental model was used to fit plasma PR-104 and PR-104A concentration-time data after intravenous (i.v.) dosing of humans, Beagle dogs, Sprague-Dawley rats and CD-1 nude mice. Intraperitoneal (i.p.) PR-104 and i.v. PR-104A dosing of mice was also investigated. Protein binding was measured in plasma from each species. Unbound drug clearances and volumes were scaled allometrically. A two-compartment model described the disposition of PR-104 and PR-104A in all four species. PR-104 was cleared rapidly by first-order (mice, rats, dogs) or mixed-order (humans) metabolism to PR-104A in the central compartment. The estimated unbound human clearance of PR104A was 211L/h/70kg, with a steady state unbound volume of 105L/70kg. The size equivalent unbound PR-104A clearance was 2.5 times faster in dogs, 0.78 times slower in rats and 0.63 times slower in mice, which may reflect reported species differences in PR-104A O-glucuronidation. The PK model demonstrates faster size equivalent clearance of PR-104A in dogs and humans than rodents. Dose-limiting myelotoxicity restricts the exposure of PR-104A in humans to approximately 25% of that achievable in mice.

PR-104 is a "pre-prodrug" designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in hypoxic regions of tumors. This study was conducted to establish the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and pharmacokinetics (PK) of PR-104 in patients with advanced solid tumors. Patients with solid tumors refractory or not amenable to conventional treatment were evaluated in a dose-escalation trial of PR-104 administered as a 1-h intravenous (IV) infusion every 3 weeks. The plasma PK of PR-104 and its primary metabolite, PR-104A, were evaluated. Twenty-seven patients received a median of two cycles of PR-104 in doses ranging from 135 to 1,400 mg/m(2). The MTD of PR-104 as a single-dose infusion every 3 weeks was established as 1,100 mg/m(2). One of six patients treated at 1,100 mg/m(2) experienced DLT of grade 3 fatigue. Above the MTD, the DLTs at 1,400 mg/m(2) were febrile neutropenia and infection with normal absolute neutrophil count. No objective responses were observed, although reductions in tumor size were observed in patients treated at doses > or = 550 mg/m(2). The plasma PK of PR-104 demonstrated rapid conversion to PR-104A, with approximately dose-linear PK of both species. PR-104 was well tolerated at a dose of 1,100 mg/m(2) administered as an IV infusion every 3 weeks. The area under the PR-104A plasma concentration-time curve at this dose exceeded that required for activity in human tumor cell cultures and xenograft models. The recommended dose of PR-104 as a single agent for phase II trials is 1,100 mg/m(2) and further trials are underway.

Journal Article Kaye, Charles, & Blee, Tony (1997). The arts in health care: A palette of possibilities . London and Bristol, Pennsylvania: Jessica Kingsley Publishers. 290 pages. ISBN 1-85302-360-4. $34.95 Get access Charles Kaye Tony Blee ( 1997 ). The arts in health care: A palette of possibilities . London and Bristol, Pennsylvania : Jessica Kingsley Publishers . 290 pages. ISBN 1-85302-360-4 . $34.95 . Mary Ann Froehlich, DMA, RMT-BC, CCLS Mary Ann Froehlich, DMA, RMT-BC, CCLS Benicia, California Search for other works by this author on: Oxford Academic PubMed Google Scholar Music Therapy Perspectives, Volume 15, Issue 2, 1997, Pages 98–99, https://doi.org/10.1093/mtp/15.2.98-a Published: 01 November 1997

Social service practitioners are challenged by serving target populations that are increasingly diverse ethnically. The challenge is compounded by budget and program cuts that limit resources for multicultural staff and training. This case study of a perinatal outreach and education program targeting low-income women from diverse ethnic backgrounds speaks to program planners and practitioners faced with these issues. The study invites a critical assessment of how "empowerment" is conceptualized and operationalized in program objectives. The impact of the social organization of an agency-driven program on the interaction between the educator and the client is examined. An alternative approach, decentralized in the diverse target communities, is suggested for future projects. This perspective requires critical consciousness on the part of planners and change agents as mediators of an empowerment process.